A prescription needs the person in the room.

The reason for considering treatment, your medical history and other medicines all matter. So does the actual product. This site can explain research, but it gives no medical advice and offers no personal assessment. The sermorelin invitation below requires a prescription after an individual clinical review.

Telehealth brings the conversation to a screen. It still needs an assessment and the right authority to practise. HHS explains how licensure depends on where the patient is. A national audience tells us little about which treatments a service can offer where you live.

Sermorelin’s former approvals ended in 2009. Its compounded preparations don’t inherit them. With compounding, a pharmacist or physician prepares the medicine to meet a patient’s need. FDA explains that compounded medicines have no FDA approval; they reach the market without its prior checks of quality, safety or effectiveness.

CJC-1295 has no approved medicine. A withdrawn compounding nomination doesn’t clear it for use or remove FDA’s safety concerns. Tesamorelin has approved products, but its status as a biologic matters here: biologics don’t qualify for the federal drug-compounding exemptions. A prescription alone doesn’t change that. Listing all three names here doesn’t make them interchangeable prescription options.

Promise Peptides has a sermorelin prescribing page. A clinician licensed in the U.S. considers your request individually and may refuse to prescribe. Patients must be in the U.S.; availability also turns on the treatment and state. The compounded medicine carries no FDA approval.

A useful question for that conversation is what change treatment is meant to bring, and what evidence supports it for someone in your situation. There’s also room to ask which preparation is being considered and what risks remain uncertain. A higher laboratory reading alone might not answer the question that made you look into treatment.